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Resumo
Objectivos: Apesar da validação de vários algo-
ritmos de selecção de mulheres pós-menopáusicas
(MPM) para realização de dual-energy x-ray absor-
ptiometry (DEXA), a informação sobre a sua utili-
dade clínica é escassa. Foi nosso objectivo avaliar
o desempenho e repercussão económica do uso de
cinco desses algoritmos em MPM Portuguesas.
Métodos: Foram incluídas 588 MPM e considera-
dos cinco algoritmos simples de decisão: ORAI,
ABONE, Body Weight Criterion, OSTA e uma versão
modificada do OSTA (OST). Calcularam-se sensibi-
lidades, especificidades, valores preditivos, áreas
da curva under the receiver operating characteristic
(AUROC) e estimativas económicas.
Resultados: As sensibilidades variaram entre 71.2%-
80.8% e a AUROC entre 0.611-0.674. Nas MPM com
≥65 anos, a utilização de qualquer um dos algo-
ritmos traduziu-se em custos adicionais ou pou-
pança residual. Nas MPM com ≥55 e <65 anos, con-
siderando a poupança absoluta, o ABONE tem o
melhor desempenho, mas considerando a poupan-
ça por fractura evitável, o ORAI assume a liderança,
seguido pelo BWC. No grupo com ≥40 e <55 anos, a
opção mais rentável em termos de poupança abso-
luta seria a de não realizar DEXA a ninguém. No en-
tanto, considerando a poupança por fractura evitá-
vel, o BWC afigura-se como o mais vantajoso.
Conclusões: Este estudo fornece evidência da va-
lidade destes instrumentos como algoritmos úteis
para a selecção de MPM para realização de DEXA.
Considerando os resultados e a importância da
simplicidade do algoritmo, sugerimos a seguinte
estratégia nas MPM Portuguesas: 1) Idade ≥65 anos:
realizar DEXA independentemente de outros fac-
tores de risco. 2) Idade <65 anos: realizar DEXA se
peso <70Kg.
*Serviço de Reumatologia dos Hospitais da Universidade de
Coimbra, Coimbra, Portugal
Note:This study was the winner of the “Osteoporosis Prize,
Portuguese Society of Rheumatology/Merck Sharp & Dohme,
2007/2008.
Abstract
Objectives: Although several algorithms have been
proposed to select postmenopausal women (PMW)
for dual-energy x-ray absorptiometry (DEXA) mea-
surements, information on their utility in clinical
practice is scarce. Our aim was to assess the utility
and the economic repercussion of the use of five of
these algorithms in Portuguese postmenopausal
women.
Methods: We included 588 PMW and selected five
simple algorithms: ORAI, ABONE, Body Weight Cri-
terion, OSTA and a modified version of OSTA (OST).
Sensitivities, specificities, predictive values, areas
under the receiver operating characteristic curve
(AUROC) and economic estimates were computed.
Results: Sensitivities ranged between 71.2%-80.8%
and AUROC between 0.611-0.674. In PMW aged ≥65
years (Y), the use of any of the algorithms would
cause extra costs or a residual saving. In PMW aged
≥55 and <65Y, considering total savings, ABONE
had the best performance, but considering savings
per preventable fracture, ORAI assumed the lead,
followed by BWC. In the age group ≥40 and <55Y,
the most profitable option considering total savings
would be not doing DEXA to anyone; considering
savings per preventable fracture, BWC figures as
the most useful.
Conclusions: This study provides evidence for the
validity of all the selected tools as useful algorithms
to select PMW for DEXA. On the basis of our results
and considering the importance of simplicity in the
applicability of an algorithm, we would suggest the
following strategy in Portuguese PMW: 1) Aged ≥65Y:
perform DEXA irrespective of other risk factors. 2)
Aged <65Y: perform DEXA if body weight <70Kg.
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Introduction
Osteoporotic fractures are a major cause of morbi-
dity and mortality, representing an enormous
health care burden in developed countries.1 At least
half of all postmenopausal women will experience
fractures during their lifetime.1 Bone mineral den-
sity (BMD) is the most important independent pre-
dictor of osteoporotic fracture and each standard
deviation reduction in BMD is associated with a 1.5
to 2.5-fold increase in fracture risk.2 The importan-
ce of BMD is reinforced because it represents one
of the few risk factors that can be changed leading
to effective prevention of fractures.
Dual-energy X-ray absorptiometry (DEXA) is the
gold-standard for the diagnosis of osteoporosis,3
the lumbar spine and the hip being the preferred
measurement sites to this purpose.4,5 Mass scree-
ning for osteoporosis is not recommended becau-
se there is considerable overlap of BMD values
between those who fracture and those who don´t.6
Cost-effectiveness is also an issue. However, DEXA
testing in high-risk groups is essential to identify
appropriate candidates for preventive interventi-
ons to avoid  further bone loss and fracture.7 Thus,
from the population point of view, it is essential to
develop and adopt the best strategies for the selec-
tion of the population where DEXA testing achie-
ves the highest effectiveness.6
A recent review of the clinical applications of bo-
ne densitometry suggests that clinicians need to-
ols to identify patients most likely to benefit from
DEXA testing.8 A simple risk assessment tool may
also have value for increasing the awareness of os-
teoporosis and for encouraging more efficient use
of BMD measurements, that is, in patients who
have a higher probability of low BMD, especially in
otherwise healthy, asymptomatic patients. Several
studies have examined and confirmed the ability of
individual risk factors to identify postmenopausal
women likely to have osteoporosis and some have
proposed simple composite tools obtained by
questionnaire and based on a score.9-19 While these
rules currently use a single cut point for deciding
whether to test or not, it has been suggested that
two cut points are preferable, as they allow the stra-
tification of the likelihood of osteoporosis as low,
moderate or high.12-16,20 As a risk index, women at
low risk would not require a BMD test, those with
moderate risk would be recommended for BMD
testing and those at high risk could be treated to
prevent fracture without the need for BMD tes-
ting.16,20
The Portuguese Society of Rheumatology and
the Portuguese Society of Metabolic Bone Disea-
ses recommend the selection of women for BMD
according to the presence of major and minor risk
factors, or according to risk assessment tools.21 Se-
veral guidelines/algorithms to identify high risk
subjects have been published.3,4,21-23
However, the evidence for the utility of these ru-
les in a clinical setting is scarce.20,24-28 Moreover, the
performance of such algorithms in identifying low
bone density has never been tested in the Portu-
guese population. Their utility is not necessarily
the same in different populations, as the contribu-
tion of different osteoporotic factors varies in dif-
ferent countries and areas. 
In this study we evaluated and compared the
performance of five simple decision algorithms for
osteoporosis risk in a large sample of Portuguese
postmenopausal women. The benefit of a second
cut point to convert each decision rule into a risk
index (low, moderate or high risk for osteoporosis)
was also evaluated. We expanded the analysis be-
yond the usual description of sensitivity and simi-
lar qualities, to explore the impact of each algo-
rithm on the absolute incidence of fractures and
their economic burden.
Materials and methods
Population and data collection
Data collection took place in Santo António dos
Olivais (SAOL), Coimbra, Portugal, in the years of
1998 and 1999. The methodology was previously
described.29 This county has a mixture of a rural
and an urban population, representing epidemio-
logical patterns of age and gender distribution, in-
come and consumer habits considered to be simi-
lar to those of the general Portuguese population.
It has about 25000 inhabitants. Residents were ran-
domly selected from the 19000 registered voters
following a computer-generated random number
list, stratified to gender and 5 year age-groups. Pe-
ople were invited to participate by mail explaining
the nature and purposes of the study. There were
no exclusion criteria. Non-respondents were con-
tacted a second time. We aimed at a total of at le-
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ast 1600 participants. A total of 6000 invitations
were sent out before this number was reached;
1100 letters bounced back due to change in ad-
dress, death and other reasons. Altogether 1745 ac-
cepted to participate. From final analysis 73 parti-
cipants were excluded due to incomplete data or
unresolved technical difficulties in the DEXA scan.
Reliable BMD of the lumbar spine and hip was
available for 1672 participants: 1208 women and
464 men.
Participants responded to a comprehensive
questionnaire regarding risk factors for osteoporo-
sis in personal and family history. Height and
weight were recorded. DEXA scans of the spine and
proximal femur were performed, using a Hologic
QDR 4500/c bone densitometer. Scans were per-
formed and analyzed according to the manufactu-
rer’s instructions. For the purposes of this study all
postmenopausal women with DEXA scans were
included (study cohort=588).
Selection of the decision algorithms and 
calculation of their scores
Based on a critical review of the literature, with
consideration of published performance indica-
tors and simplicity, we selected 5 simple decision
algorithms to test in our study cohort: the Osteo-
porosis Risk Assessment Instrument13 (ORAI), the
Age, Body Size, No Estrogen criterion9 (ABONE),
the Body Weight Criterion10 (BWC), the Osteoporo-
sis Self-Assessment Tool for Asians12 (OSTA) and a
modified version of the OSTA equation12, 14 (OST).
Their scoring methods, with previously validated
selection cut-off points, are presented in Table I. All
the information needed was available in the SAOL
database.
Each decision algorithm was converted into a
risk index to differentiate between low, moderate
and high risk for osteoporosis, adopting previously
validated cut-off points,12-16,20 as follows: ORAI - low
risk, a score <9, moderate risk, a score between 9
and 17, high risk, a score >17. BWC - low risk, ≥70
Kg, moderate risk, 57 to 69.9 Kg, high risk, <57 Kg.
OSTA and OST - low risk, a score >1, moderate risk,
a score of -3 to 1, high risk, a score <-3. Given that,
to our knowledge, the ABONE has not been previo-
usly evaluated using two cut points, we chose to
consider: low risk, a score ≤1, moderate risk, a sco-
re of 2, high risk, a score of 3, as these are the only
possible scores in this algorithm. 
All 5 decision algorithm were applied to each
one of the 588 postmenopausal women belonging
to our study cohort. Age was calculated to the date
of the DEXA scan. 
Gold standard
BMD values as assessed by DEXA were used as the
gold standard for diagnosing osteoporosis. We used
Table I. Five simple decision rules for bone mineral density testing among postmenopausal women 
Factor Score
Osteoporosis Risk Assessment Instrument (ORAI), test if score ≥9
Age 55-64 years 5
Age 65-74 years 9
Age ≥75 years 15
Weight 60-69.9 Kg 3
Weight <60 Kg 9
Not currently taking oestrogen 2
Age, Body Size, No Estrogen (ABONE), test if score ≥2
Age >65 1
Weight <63.5 kg 1
Never used oral contraceptive or oestrogen therapy for at least 6 months 1
Body weight criterion (BWC), test if
Weight <70 Kg
Osteoporosis Self-assessment Tool for Asians (OSTA), test if score < 2
0.2*body weight in Kg (truncate to yield an integer) - 0.2*age in years (truncate to yield an integer)
Osteoporosis Self-assessment Tool (OST), test if score < 2
0.2*(body weight in Kg - age in years), truncate to yield an integer
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the World Health Organization (WHO) thresholds
to classify our patients into 3 diagnostic catego-
ries: normal (T-score ≥–1.0 SD), osteopenic (–1.0
>T-score >–2.5 SD) or osteoporotic (T-score ≤–2.5
SD). The young normal reference values used for
the calculation of T-scores were NHANES III refe-
rence for the hip30 and the HOLOGIC Caucasian re-
ference database for the spine. In each case, the
lowest BMD T-score at the lumbar spine (L1–L4),
femoral neck or total hip was considered. DEXA
results were available for all the 588 postmenopau-
sal women integrating the study cohort and there-
fore the gold standard for osteoporosis was availa-
ble for all of them. When details for only one site
were available (n=1), BMD was categorized based
on that single site.
Statistical analysis and evaluation of the 
algorithms’ performance for identifying 
osteoporosis
Descriptive characteristics of the study population
were tabulated as means and standard deviations
(SD), or proportions as applicable. Differences
among groups of patients were calculated by ana-
lysis of variance or chi-squared test as applicable. 
In order to evaluate the performance of the five
selected algorithms, the sensitivity, specificity, po-
sitive predictive value (PPV), negative predictive
value (NPV) and the area under the receiver ope-
rating characteristic (AUROC) curve of each deci-
sion algorithm for selecting women with osteopo-
rosis by BMD testing (the gold standard) were de-
termined. In addition, the predictive values for
identifying osteoporosis for each risk index of low,
moderate and high risk were calculated. 
Exact binomial 95% confidence intervals31 (CI)
were calculated for sensitivities, specificities and
predictive values. Sensitivities, specificities and
predictive values are proportions calculated accor-
ding to the results obtained in our sample popula-
tion. Therefore, they are point estimators in a ran-
dom sample from the general PMW population. A
confidence interval for the binomial parameter
broadens that point estimate out, reflecting the
uncertainty associated with the limited size of the
sample.
Sensitivity was defined as the proportion of wo-
men with osteoporosis (DEXA T-score ≤–2.5 SD)
who tested positive on the decision algorithm (in-
dication for DEXA in the binomial classification)
and specificity was defined as the proportion of
women without osteoporosis (DEXA T-score >–2.5
SD) who tested normal on the decision algorithm
(having index values in the range considered low
risk). Positive predictive value was defined as the
proportion of women with a positive algorithm
score who were actual cases of osteoporosis and
negative predictive value was defined as the pro-
portion of women with a negative algorithm result
who were actual non-cases of osteoporosis. The
AUROC curve was used as a measure of the overall
ability of each strategy to discriminate between
postmenopausal women with and without osteo-
porosis.32 An area of 1 represents a perfect test; an
area ≤0.5 represents a worthless test.
Statistical analysis was performed using SPSS
14.0 for Windows.
Economic analysis
The analysis of the algorithms’ performance for
identifying osteoporosis was expanded by explo-
ring the impact of each algorithm upon the savings
in DEXA, the probability of fracture and the eco-
nomic repercussions of both. 
The number of lost cases of osteoporosis, pre-
ventable fractures, total savings and savings per
preventable fracture were computed from the pre-
valence of osteoporosis in the different age groups
and sensitivities. The estimated absolute risk for
“any type of osteoporotic fracture” over ten years
was calculated according to data published by Ka-
nis et al.33
For economic calculations we used the present
official cost of DEXA scanning for two sites within
the Portuguese National Health System: 126.60€
(Portaria 132/2003). The hospital costs for fractu-
res were estimated at 3000€ based on the official
2007 reimbursement table of Portuguese hospitals
according to “Homogeneous Diagnostic Groups”:
around 4000€ per hip and humerus fractures and
1700€ for forearm fractures. For clarity, these cal-
culations were estimated for a population of 10000,
extrapolating from our data, and rounded to the
nearest unit, for fractures and DEXA scans, and to
the nearest hundred for costs.
Therefore, economic items (Table VII) were
computed as follows (fractions rather than percen-
tages are used in the formulas below):
a) lost cases of osteoporosis: (1-sensitivity)*fracti-
on of women with osteoporosis within the age
group*10000
b) ten-year fracture probability: mean femoral
neck T-score of osteoporotic women was calcu-
lated for each age group in our cohort and ba-
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sed on that mean result, the 10-year fracture
probability for each age group was established
according to the data published by Kanis et al 33
(who based his estimations on femoral neck T-
-score)
c) absolute excess fractures over 10 years (this is
the 10-year estimation of the total number of
fractures in a 10000 population, due to lost ca-
ses of osteoporosis): lost cases of osteoporo-
sis*ten-year fracture probability, that is a*b
d) hospital costs for excess fractures (these are the
direct hospital costs caused by the absolute ex-
cess of fractures over 10 years due to lost cases
of osteoporosis): absolute excess fractures over
10 years*3000€, that is c*3000€
e) number of avoided DEXA scans (this is the num-
ber of DEXA scans that was not performed due
to the use of a selection algorithm, compared
with the “scan all” option): (1-fraction of wo-
men selected for DEXA)*10000
f) savings with DEXA scans: number of avoided
DEXA scans*126.60€, that is e*126.60€
g) net balance: savings with DEXA scans minus
hospital costs for excess fractures, that is f mi-
nus d
h) net balance per preventable fracture (this is the
net balance adjusted to the 10-year estimation
of the total number of fractures in a 10000 po-
pulation): net balance÷absolute excess fractures
over 10 years, that is g÷c.
Results
Our study population included 588 postmenopau-
sal women aged 42 to 87 years, with a mean age of
60 years. Table II summarizes the descriptive cha-
racteristics of the study cohort, including age dis-
tribution, WHO criteria and T-score. A large num-
ber of participants with less than 65 years were in-
cluded (72.8%).
Table III summarizes the descriptive characte-
Table II. Summary of descriptive characteristics of the postmenopausal study cohort (n=588)
Age (years, mean ± SD) 60.18 ± 8.57
Age group - n (%)
Age ≥40 and <55 years 204 (34,7)
Age ≥55 and <65 years 224 (38,1)
Age ≥65 years 160 (27,2)
Time since menopause (years, mean ± SD) 12.30 ± 9.25
Height (cm, mean ± SD) 155.90 ± 6.24
Weight (Kg, mean ± SD) 67.18 ± 10.88
Body mass index (Kg/m2, mean ± SD) 27.68 ± 4.46
HRT use – n (%)
Never 345 (58.7)
Past 82 (13.9)
Current 153 (26.0)
Missing 8 (1.4)
WHO diagnostic categories - n (%)
Normal 121 (20.6)
Osteopenia 311 (52.9)
Osteoporosis 156 (26.5)
T-Score (mean ± SD)
Lumbar spine -1.57 ± 1.25
Femoral neck -1.28 ± 1.02
Total hip -0.66 ± 1.01
ORAI score (mean ± SD) 9.64 ± 6.06
ABONE score (mean ± SD) 1.43 ± 0.87
OSTA score (mean ± SD) 1.47 ± 2.86
OST score (mean ± SD) 1.19 ± 2.50
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ristics of the study cohort stratified on the basis of
the three WHO diagnostic categories.
The overall percentage of osteoporosis at lum-
bar spine, femoral neck or total hip was 26.5%
(n=156). The percentage of osteoporosis at each
measurement site was 22.6% at lumbar spine
(n=133), 11.1% at femoral neck (n=65) and 3.4% at
total hip (n=20). The percentage of women with
osteoporosis increased with age from 12.3%
among women aged ≥40 and <55 years (25/204),
26.8% among women aged ≥55 and <65 years
(60/224) and 44.4% among women aged ≥65 years
(n=71/160). The WHO diagnostic categories show
significant differences regarding all main risk fac-
tors for osteoporosis, and also for all the risk as-
sessment tools under scrutiny. 
Table IV shows the sensitivity, specificity, predic-
tive values and area under ROC curve of each de-
cision rule for selecting women with osteoporosis
for BMD testing in the study cohort (n=588). All
screening tools, when applied with single cut-off
point, showed sensitivities above 70%. Specificity
was lower, ranging from 44.7% to 63.7%. Negative
predictive value was also quite high in all algo-
rithms (84.6% to 88.4%). The AUROC curve is a me-
asure of the test accuracy32 and in our study it ran-
ged between 0.611 and 0.669. The AUROC curve
95% CI did not include 0.5 for any of the algo-
rithms, confirming their capacity to distinguish
between women with and without osteoporosis.
Table V summarizes the percentage of women
selected for DEXA scanning as well as sensitivity,
specificity, PPV and NPV for each age group. The
qualities of the screening tools are different when
applied to the different age groups. Overall, most
of the screening tools tend to perform better, in
terms of sensitivity, in the older age groups. BWC
is the only exception to this observation.
Table VI shows the percentage of women with
low, moderate, or high risk for osteoporosis by each
decision algorithm after application of two cut-off
points and corresponding negative (for low risk
group) or positive predictive values (for moderate
and high risk groups). The low risk group repre-
sents the postmenopausal women not selected for
DEXA after applying an algorithm. The distinction
between moderate and high risk groups is an at-
tempt of stratification of the postmenopausal wo-
Table III. Summary of descriptive characteristics of the postmenopausal study cohort (n=588) according to
the three WHO diagnostic categories†
Normal Osteopenia Osteoporosis
(n=121) (n=311) (n=156) p
Age (years, mean ± SD) 56.10 ± 6.50 59.49 ± 8.33 64.71 ± 8.49 p<0.001
Age group - n (%) p<0.001
Age ≥40 and <55 years 67 (55.4)‡ 112 (36) 25 (12.3)‡
Age ≥55 and <65 years 40 (33.1) 124 (39.9) 60 (26.8)
Age ≥65 years 14 (11.6)‡ 75 (24.1) 71 (44.4)‡
Time since menopause (years, mean ± SD) 7.55 ± 6.66 11.73 ± 8.95 17.17 ± 9.38 p<0.001
Height (cm, mean ± SD) 158.21 ± 5.79 156.20 ± 5.90 153.51 ± 6.46 p<0.001
Weight (Kg, mean ± SD) 71.52 ± 10.15 67.4 ± 10.28 63.39 ± 11.33 p<0.001
Body mass index (Kg/m2, mean ± SD) 28.62 ± 4.19 27.69 ± 4.42 26.92 ± 4.63 p=0.007
HRT use (%) p<0.001
Never 52 (43.0)‡ 176 (56.6) 117 (75.0)‡
Past 11 (9.1) 47 (15.1) 24 (15.4)
Current 56 (46.3)‡ 84 (27.0) 13 (8.3)‡
Missing 2 (1.7) 4 (1.3) 2 (1.3)
ORAI score (mean ± SD) 6.00 ± 4.69 9.14 ± 5.56 13.45 ± 5.89 p<0.001
ABONE score (mean ± SD) 0.93 ± 0.73 1.38 ± 0.81 1.94 ± 0.80 p<0.001
OSTA score (mean ± SD) 3.16 ± 2.36 1.65 ± 2.52 -0.21 ± 2.96 p<0.001
OST score (mean ± SD) 2.64 ± 2.26 1.33 ± 2.22 -0.23 ± 2.49 p<0.001
†The lowest BMD T-score at the lumbar spine, femoral neck or total hip was considered.
‡Significant adjusted standardized residuals.We used adjusted standardized residuals to identify the contribution of different cells to the
significance of the chi-square test.
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men selected for DEXA after applying an algo-
rithm. This has been suggested on the basis that it
might exclude the need for DEXA in high risk indi-
viduals (who could be treated without DEXA).13 The
positive predictive values are quite low, even for the
high risk groups. This means that a considerable
proportion of patients would be wrongly selected
for treatment if a high risk score in any algorithm
was taken as direct indication for treatment wi-
thout performing DEXA. The NPV associated with
low risk is much more satisfactory.
Finally, Table VII shows the estimates of lost ca-
ses of osteoporosis, absolute excess fractures and
cost savings as a consequence of applying each se-
lected algorithm per age-group, as compared with
the «scan all» option. For clarity, numbers were cal-
culated for a population of 10000 and rounded to
the nearest unit, for fractures and DEXA scans, and
to the nearest hundred for costs.
The most restrictive algorithms result in greater
savings on DEXA scans, but at the cost of larger
number of ignored osteoporosis cases and subse-
quent fractures. Total savings may be higher but in-
direct costs, including suffering from fracture, will
also be higher. The calculation of “savings per pre-
ventable fracture” is an attempt to bring this into
account – it may be seen as the savings available
to cover indirect costs of fracture, after having co-
vered direct hospital costs. The negative values in
the two last columns for those aged ≥65 years mean
that savings with DEXA would not be enough to co-
ver for direct hospital costs.
Discussion
There are three recommended steps in developing
and testing tools to aid clinical decision-making:
development, validation in several cohorts and im-
pact assessment. Information on their utility in dif-
ferent populations is especially important in order
to establish the generalizability of these approa-
ches and to assure their validity in clinical practi-
ce as applied in different clinical and epidemiolo-
gical settings.13
We analyzed the value of 5 simple decision al-
gorithms for selecting individuals for bone mine-
ral testing in 588 Portuguese postmenopausal wo-
men; mean age was 60 years and mean time since
menopause was 12 years. The relevance of these
decision rules could decrease in the future. There
is a progressive tendency to recommend the iden-
tification of individuals for treatment based on a
comprehensive fracture risk assessment rather
than BMD status alone.34 The BMD would be one
among other factors to predict fracture risk. Howe-
ver, the importance of the WHO categories in the
decision-making remains high and DEXA measu-
rements will still be necessary in the future to in-
corporate BMD values into the fracture risk equa-
tions. Therefore, the performance of decision algo-
rithms for identifying low bone density in postme-
nopausal women is a matter of great importance.
Compared to the majority of previous reports,
this study had the virtue of not being retrospecti-
ve. It was a cross-sectional study, performed in a
Table IV. Percentage of women selected for DEXA, sensitivity, specificity, predictive values and area under
ROC of each decision rule for selecting women with osteoporosis† for BMD in the study cohort (n=588) 
Percentage of
women selected Sensitivity, % Specificity, % PPV, % NPV, % AUROC
for DEXA (95% CI) (95%CI) (95% CI) (95% CI) (95% CI)
ORAI 56.0 80.8 53.0 38.3 88.4 0.669
(51.8-60.0) (73.7-86.6) (48.2-57.8) (33.0-43.8) (83.9-92.1) (0.622-0.716)
ABONE 45.6 71.2 63.7 41.4 85.9 0.674
(41.5-49.7) (63.4-78.1) (58.9-68.2) (35.5-47.6) (81.6-90.0) (0.625-0.723)
BWC 61.2 77.6 44.7 33.6 84.6 0.611
(57.2-65.2) (70.2-83.9) (39.9-49.5) (28.8-38.8) (79.3-89.1) (0.562-0.661)
OSTA 51.0 75.6 57.9 39.3 86.8 0.668
(46.9-55.1) (68.1-82.1) (52.1-62.6) (33,8-45.1) (82.3-90.5) (0.619-0.716)
OST 58.5 80.8 49.5 36.6 87.7 0.652
(54.4-62.5) (73.7-86.6) (44.7-54.4) (31.5-42.0) (82.9-91.6) (0.604-0.699)
†BMD T-score ≤-2,5 by lowest value at the lumbar spine, femoral neck or total hip was considered.
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Table V. Percentage of women selected, sensitivity, specificity and predictive values of each decision 
algorithm for selecting women with osteoporosis† for BMD, according to the age groups
Percentage of
women selected Sensitivity, % Specificity, % PPV, % NPV, %
for DEXA (95% CI) (95%CI) (95% CI) (95% CI)
ORAI
≤40 and <55 years‡ 26,0 48.0 77.1 22.6 91.4
(20.1-32.6) (27.8-69.0) (70.2-83.0) (12.3-36.2) (85.7-95.3)
≥55 and <65 years‡ 51.8 71.7 55.5 37.1 84.3
(45.0-58.5) (58.6-82.6) (47.5-63.2) (28.3-46.5) (76.0-90.6)
<65 years‡ 39.5 64.7 66.8 32.5 88.4
(34.8-44.3) (53.6-74.8) (61.5-71.7) (25.6-40.2) (83.9-92.1)
≥65 years‡ 100.0 100.0 N.A. 44.4 N.A.
(97.7-100.0) (94.9-100.0) (36.5-52.4)
ABONE
≥40 and <55 years‡ 24.5 52.0 79.3 26.0 92.3
(18.8-31.0) (31.3-72.2) (72.7-85.0) (14.6-40.3) (86.8-95.9)
≥55 and <65 years‡ 27.7 48.3 79.9 46.8 80.9
(21.9-34.0) (35.2-61.6) (72.9-85.7) (34.0-59.9) (74.0-86.6)
<65 years‡ 26.2 49.4 79.6 37.5 86.4
(22.1-30.6) (38.4-60.5) (74.9-83.7) (28.5-47.2) (82.1-90.0)
≥65 years‡ 97.5 97.2 2.2 44.2 50.0
(93.7-99.3) (90.2-99.7) (0.3-7.9) (36.3-52.4) (6.8-93.2)
BWC
≥40 and <55 years‡ 60.3 88.0 43.6 17.9 96.3
(53.2-67.1) (68.8-97.5) (36.2-51.2) (11.6-25.8) (89.6-99.2)
≥55 and <65 years‡ 59.8 75.0 45.7 33.6 83.3
(53.1-66.3) (62.1-85.3) (37.9-53.7) (25.7-42.3) (74.0-90.4)
<65 years‡ 60.0 78.8 44.6 26.1 89.5
(55.2-64.7) (68.6-86.9) (39.3-50.0) (20.8-31.9) (83.9-93.6)
≥65 years‡ 64.4 76.1 44.9 52.4 70.2
(56.4-71.8) (64.5-85.4) (34.4-55.9) (42.4-62.4) (56.6-81.6)
OSTA
≥40 and <55 years‡ 23.5 44.0 79.3 22.9 91.0
(17.9-30.0) (24.4-65.1) (72.7-85.0) (12.0-37.3) (85.4-95.0)
≥55 and <65 years‡ 51.3 68.3 54.9 35.7 82.6
(44.6-58.1) (55.0-79.7) (46.9-62.7) (26.9-45.1) (74.1-89.2)
<65 years‡ 38.1 61.2 67.6 31.9 87.5
(33.5-42.9) (50.0-71.6) (62.4-72.6) (24.8-39.7) (83.0-91.3)
≥65 years‡ 85.6 93.0 20.2 48.2 78.3
(79.2-90.7) (84.3-97.7) (12.5-30.1) (39.6-56.9) (56.3-92.5)
OST
≥40 and <55 years‡ 31.4 52.0 71.5 20.3 91.4
(25.1-38.2) (31.3-72.2) (64.3-78.0) (11.3-32.2) (85.5-95.5)
≥55 and <65 years‡ 62.1 75.0 42.7 32.4 82.4
(55.4-68.4) (62.1-85.3) (35.0-50.6) (24.7-40.8) (72.6-89.8)
<65 years‡ 47.4 68.2 57.7 28.6 88.0
(42.6-52.3) (57.2-77.9) (52.3-63.0) (22.5-35.3) (83.0-91.9)
≥65 years‡ 88.1 95.8 18.0 48.2 84.2
(82.1-92.7) (88.1-99.1) (10.6-27.6) (39.7-56.8) (60.4-96.6)
†BMD T-score ≤-2,5 by lowest value at the lumbar spine, femoral neck or total hip was considered.
‡Percentage of women with osteoporosis: 12.3% among women aged ≥40 and <55 years (25/204), 26.8% among women aged ≥55 and
<65 years (60/224), 19.9% among women aged <65 years (85/428) and 44.4% among women aged ≥65 years (71/160).
N.A.: Not applicable.
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non-clinical setting and in a random population.
Such results are more probably generalizable than
if the sample had been submitted to imprecise pre-
selection. Because the study sample was randomly
selected with no clinical exclusion criteria, we can-
not be sure that all osteoporotic patients had pri-
mary osteoporosis; however, the prevalence of
known secondary causes of osteoporosis in our
sample was very small, and this aspect probably
has very little effect on the value of our study. Our
population had a wide representation in terms of
age, height, weight, oestrogen use and BMD status
(Table II). 
An important point of this study is the high pro-
†BMD T-score < -2.5 by lowest value at the lumbar spine, femoral neck or total hip was considered. N.A. Not applicable.
Table VI. Percentage of women with low, moderate, or high risk for osteoporosis† by each decision rule and
corresponding positive predictive values
Distribution of
study sample, % PPV, % NPV
(95% CI) (95% CI) (95% CI)
ORAI
Low (< 9) 44.0 N.A. 88.4
(40.0-48.2) (84.0-92.1)
Moderate (9 to 17) 45.7 33.8 N.A.
(41.7-49.9) (28.2-39.8)
High (> 17) 10.2 58.3 N.A
(7.9-12.9) (44.9-70.9)
ABONE
Low (= 1) 54.4 N.A. 85.9
(50.3-58.5) (81.6-89.6)
Moderate (= 2) 34.2 35.3 N.A.
(30.4-38.2) (28.7-42.4)
High (= 3) 11.4 59.7 N.A.
(8.9-14.1) (47.0-71.5)
BWC
Low (≥ 70) 38.8 N.A. 84.6
(34.8-42.9) (79.3-89.1)
Moderate (57 to 69.9) 44.4 29.1 N.A.
(40.3-48.5) (23.7-35.0)
High (< 57) 16.8 45.5 N.A.
(13.9-20.1) (35.4-55.8)
OSTA
Low (> 1) 49.0 N.A. 86.8
(44.9-53.1) (82.3-90.5)
Moderate (-3 to 1) 46.8 36.7 N.A.
(42.7-50.9) (31.0-42.7)
High (< -3) 4.3 68.0 N.A.
(2.8-6.2) (46.5-85.1)
OST
Low (> 1) 41.5 N.A. 87.7
(37.5-45.6) (82.9-91.6)
Moderate (-3 to 1) 55.3 34.8 N.A.
(51.2-59.3) (29.6-40.2)
High (< -3) 3.2 68.4 N.A.
(1.9-5.0) (43.5-87.4)
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portion of women aged <65 years (72.8%). Indeed,
this is the group where decision-aid tools are es-
pecially needed. In fact, several authorities (inclu-
ding Portuguese), recommend that BMD testing
should be performed in all women aged ≥65 years
regardless of additional risk factors.21, 23
The representativeness of our sample is further
supported by the strong relationship between
WHO status and well known risk factors for osteo-
porosis, including age, years after menopause,
height, weight, BMI and oestrogen use (Table III).
The relationship with the algorithms tested here is
also clear.
The choice of the best performing decision-aid
tool is complex and needs to consider a variety of
aspects. At a simple level one would be tempted to
simply choose the test with the best sensitivity and
specificity or AUROC curve. Ideally, one screening
aDerived from Kanis et al31 for this age group, assuming the average femoral neck T-score among osteoporotic women in each age group.
bAbsolute excess fractures: those estimated to occur over 10 years, in 10000 population due to the osteoporosis cases lost to treatment
as a consequence of applying the selection algorithm.
cZero option: hypothetical decision of not scanning anyone in this age group.
Table VII. Estimates of lost cases of osteoporosis, absolute excess fractures and cost savings as a 
consequence of applying each selected algorithm per age-group, as compared with the "scan all" option.
Numbers extrapolated from the observed data to 10000 population.
Number Net Net 
10 year Hospital of Savings balance balance 
10 year absolute costs for avoided with  (savings per 
Lost cases of fracture excess excess DEXA DEXA minus preventable
Algorithm osteoporosis probabilityb fracturesb fractures scans scans costs) fracture
≥65 years: 44.4% of women with osteoporosis (71/160), average femoral neck T-score -2.41
ORAI 0 23.1% 0 0€ 0 0€
ABONE 125 23.1% 29 86,600€ 250 31,700€ -55,000€ -1,900€
BWC 1063 23.1% 246 736,700€ 3563 451,100€ -285,600€ -1,200€
OSTA 313 23.1% 72 216,900€ 1438 182,100€ -34,900€ -500€
OST 188 23.1% 43 130,300€ 1188 150,400€ 20,100€ 500€
Zero optionc 4438 23.1% 1025 3,075,500€ 10000 1,266,000€ -1,809,500€ -1,800€
≥55 and <65 years: 26.8% of women with osteoporosis (60/224), average femoral neck T-score -2.07
ORAI 759 11.9% 90 271,000€ 4821 610,300€ 339,400€ 3,800€
ABONE 1384 11.9% 165 494,100€ 7232 915,600€ 421,500€ 2,600€
BWC 670 11.9% 80 239,200€ 4018 508,700€ 269,500€ 3,400€
OSTA 848 11.9% 101 302,700€ 4866 616,000€ 313,300€ 3,100€
OST 670 11.9% 80 239,200€ 3795 480,400€ 241,300€ 3,000€
Zero optionc 2679 11.9% 319 956,400€ 10000 1,266,000€ 309,600€ 1,000€
≥40 and <55 years: 12.3% of women with osteoporosis (25/204), average femoral neck T-score -1.99
ORAI 637 7.9% 50 151,000€ 7402 937,100 786,100€ 15,600€
ABONE 588 7.9% 46 139,400€ 7549 955,700 816,300€ 17,600€
BWC 147 7.9% 12 34,800€ 3971 502,700 467,900€ 40,300€
OSTA 686 7.9% 54 162,600€ 7647 968,100 805,500€ 14,900€
OST 588 7.9% 46 139,400€ 6863 868,900 729,500€ 15,700€
Zero optionc 1225 7.9% 97 290,300€ 10000 1,266,000 975,700€ 10,100€
<65 years: 19.9% of women with osteoporosis (85/428), average femoral neck T-score -2.05
ORAI 701 9.8% 69 206,100€ 6051 766,100€ 560,000€ 8,200€
ABONE 1005 9.8% 98 295,500€ 7383 934,700€ 639,200€ 6,500€
BWC 421 9.8% 41 123,800€ 3995 505,800€ 383,000€ 9,300€
OSTA 771 9.8% 76 226,700€ 6192 783,900€ 557,200€ 7,400€
OST 631 9.8% 62 185,500€ 5257 665,500€ 480,000€ 7,800€
Zero optionc 1986 9.8% 195 583,900€ 10000 1,266,000€ 682,100€ 3,500€
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test should be 100% sensitive and 100% specific.
However, in practice this doesn’t occur: sensitivity
and specificity are usually inversely related: the
better a test is at correctly identifying people who
have the disease (sensitivity), the worse it is at cor-
rectly identifying people who are well (specificity)
and vice-versa35. The relative importance given to
one or the other of these parameters will depend
on the prevalence of the condition in the target po-
pulation and on the severity of the condition. The
higher the prevalence and/or severity of the con-
dition, the more one would value sensitivity and
negative predictive value: the loss of cases in a
highly prevalent or costly disease has a higher ne-
gative impact on the health of the population. The
lower the prevalence and/or severity of the condi-
tion, the more we would require specificity and po-
sitive predictive value: applying a screening test to
search for a relatively rare or not severe condition
requires considerable investment for a relatively
low benefit. From this perspective and as clini-
cians, we need to take into account that the impor-
tance of the densitometric diagnosis of osteoporo-
sis (“severity”) varies remarkably with age, as the
absolute risk of fracture remains relatively small
even for very low T-scores, until the age of 55, and
increases sharply after that age.33, 34 Therefore, sen-
sitivity is essential at older ages but not so crucial
in younger ages, especially before the age of 55 –
these patients are much less likely to suffer the con-
sequences of their osteoporosis in the following
few years.
All algorithms performed quite well in the ove-
rall cohort (Tables III and IV). They all presented
good discriminatory performances (AUROC curves
ranging from 0.611 to 0.674) and showed signifi-
cant differences between the normal, osteopenic
and osteoporotic groups, supporting their validity.
The sensitivity values in the overall series (71.2% to
80.8%, Table IV) were not as satisfactory as those
observed by Cadarette et al20 (91.5% to 95.3%). The
principal difference with that study is the lower
proportion of women aged <65 years in Cadaret-
te’s study (58.5%, mean age of the cohort 62.4 years)
compared to this report (72.8%, mean age of the
cohort 60.2 years). This could largely explain the
discordance. Emphasizing that age is an impor-
tant variable in determining sensitivity and speci-
ficity we observed that sensitivity increased pro-
gressively with age, except for the BWC (Table V).
This hypothesis is strengthened by the observa-
tion of lower sensitivity values (58.1% to 83.8%) by
Martínez-Aguilà et al,27 who analyzed an even yo-
unger cohort of postmenopausal women (95.5%
of women aged <65 years, mean age of the cohort
54.2 years). 
Despite the overall good performance of these
tools, the impact of age supports the need to con-
sider them according to three age groups:
1) Above 65. As osteoporosis is highly prevalent in
this age-group, most authorities recommend
performing DEXA scans in every person of this
age group. This recommendation would render
any decision algorithm as a useless intellectual
exercise, but its validity needs to be tested befo-
re we adopt it. Sensitivity, i.e. how good a test is
at correctly identifying people who have the di-
sease, would be the most useful quality of a de-
cision-aid, followed by negative predictive va-
lue, i.e. the chance that a negative result will be
correct (osteoporosis is a serious and high pre-
valent condition at this age).
2) Below 55. The prevalence of osteoporosis and
the risk associated with it are much smaller than
in older age groups. Specificity, i.e. how good a
test is at correctly identifying people who are
well, would be the most valuable characteristic
here, followed by positive predictive value, i.e
the chance that a positive test result will be cor-
rect.
3) Between 55 and 65. The group with the highest
need of a good decision algorithm. Ideally, for
this group, the risk assessment tool would ba-
lance the qualities desired for 1) and 2), as the
epidemiological background is also intermedi-
ate. Cost-effectiveness study in this group would
be even more valuable.
The recommendation for universal DEXA scan
after age 65 seems to perform quite well in our po-
pulation: 44% of women aged ≥65 years were oste-
oporotic, and presented an average femoral neck
T-score of -2.41, and a 23.1% 10-year probability of
fracture, according to Kanis et al.33 Extrapolating to
a 10000 population this osteoporotic subgroup can
be estimated to suffer 1025 potentially preventable
osteoporotic fractures over the following 10 years
(Table VII). Applying any of the algorithms to this
age group would result in a net economical loss, as-
suming the adopted methodology. The only excep-
tion would be the OST, which would result in a net
positive balance of 20100€, only 500€ per preven-
table fracture. It is obvious from Table VII, that the
worst choice, even from the purely economical
perspective would be to complete ignore the pro-
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blem (zero option). This would have an excess cost
of nearly 2 million Euros considering hospital costs
alone. The recommendation for universal DEXA
scan after age 65 is, therefore, well supported and
should be adopted, without need to consider any
other factors or algorithms.  
Regarding the intermediate age-group (≥55 and
<65 years), the choice of a preferable algorithm on
the theoretical basis exposed above is difficult, as
it is not possible to precisely decide which would
be the best balance between the different qualities
of each rule. ABONE would be the best performing
tool according to the net economic balance per
10000 population (savings of 421500€, Table VII).
However, it would be associated with the highest
number of fractures (165), except for the zero op-
tion (319). Calculations of the net balance per pre-
ventable fracture would elect ORAI for this group
with net savings of 3800€ per preventable fractu-
re. To visualize the issue it may help if we imagine
that this money could be paid as compensation
for each victim of a preventable fracture. It is not a
brilliant figure, but it is the best available. These
calculations exclude the zero option from conside-
ration and put BWC as second choice (3400€).
Looking now at the group aged below 55, only
12% of these women were osteoporotic, and pre-
sented an average femoral neck T-score of -1.99.
This can be estimated to result in 97 osteoporotic
fractures per 10000 population over the following
10 years, if left unscanned and untreated (option
zero, Table VII). Comparing with the universal ap-
plication of DEXA to all this population, the use of
any of the alternative options would result in a sig-
nificant positive net economical balance. The best
choice from the purely global economical point of
view would be to ignore the problem, i.e. choose
the zero option (total net positive balance of nearly
1 million Euros). However this would result in a
net balance per fracture victim of only 10100€ as
opposed to the 40300€ per fracture estimated from
the application of the BWC. Scanning every post-
menopausal woman below the age of 55 is the sa-
fest option, as it would identify every single case,
but it is obviously a very costly option. Applying
BWC to this age group seems to offer considerable
advantage. 
Simplicity would advise the use of the same al-
gorithm for both the younger groups. The choice
of the best is, however, difficult, as it requires com-
bined consideration of all four parameters. Twen-
ty percent of women aged <65 years were osteopo-
rotic, and presented an average femoral neck T-
-score of -2.05. This can be estimated to result in
195 potentially preventable osteoporotic fractures
per 10000 population over the following 10 years if
left totally unscanned and untreated (zero option,
Table VII). Again the zero option would give the
best global economical balance but at the cost of
the highest number of fractures. Savings per pre-
ventable fracture would be limited to 3500€. This
is far worse than what can be achieved with BWC.
This algorithm would select for DEXA 60% of the
population but would allow the avoidance of 80%
of the potentially preventable fractures. The end re-
sult is represented by a net balance per preventa-
ble fracture of 9300€, the best of the alternatives.
These results may suggest that the two younger
age groups should be treated as separate entities
given that the best strategy for each is quite diffe-
rent. However, the advantage of using a single al-
gorithm and the simplicity of BWC will probably
have an important positive impact in the practical
implementation and effectiveness of any recom-
mendation. We would, therefore, favour the choi-
ce of this risk assessment tool as the best to use for
postmenopausal women below the age of 65.
Converting the decision rules into risk indices
has been suggested on the basis that it might ex-
clude the need for DEXA on low risk individuals
(who would need no treatment), as well as in high
risk individuals (who could be treated without
DEXA).13 Our data on positive predictive value (true
osteoporotic women within the risk category) va-
lidate previously proposed cut points (Table VI)
but also preclude the approach described above.
In fact, 32% to 54.5% of women included in the
highest risk group by any of these algorithms did
not reach the WHO criteria for osteoporosis and
would be unduly treated as far as BMD goes.
In summary, this study provides evidence for
the validity of the ORAI, ABONE, BWC, OSTA and
OST as useful clinical aids to assist physicians in
making decisions about which postmenopausal
women to refer for BMD testing for the purpose of
diagnosing osteoporosis. Each rule identified over
70% of women with primary osteoporosis while li-
miting BMD testing among those with normal
BMD. The BWC seems to have a small advantage
over the alternatives in our population. It performs
at the highest level in both younger age-groups and
is exceedingly simple. 
On the basis of our results we would suggest the
following strategy for selecting postmenopausal
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women for DEXA scan, in the general Portuguese
population:
1) Aged 65 and above: perform DEXA scan irres-
pective of other risk factors.
2) Aged below 65: perform DEXA scan if body
weight is less than 70 Kg.
The value of clinical screening tools in young
postmenopausal women has been previously eva-
luated in 3 studies. Gourlay et al,24 in Belgium,
found that the OST, ORAI, and SCORE (based on
race, presence of rheumatoid arthritis, low trauma
fracture, oestrogen use, age, and weight) risk as-
sessment tools had similar discriminatory ability
to identify osteoporosis at the femoral neck in a  re-
ferral population of postmenopausal women aged
45–64 years (mean age of the cohort 56 years) com-
pared to women aged ≥65 years (mean age of the
cohort 70.7 years). Martínez-Aguilà et al 27 found
that the ORAI, OST, BWC and OSIRIS (based on
weight, age, oestrogen use and history of low im-
pact fracture) were useful as screening methods to
rule out the presence of osteoporosis and the need
for BMD scanning in young postmenopausal wo-
men (study cohort: 95.5% of women aged <65
years, mean age 54.2 years). However, the results
obtained by Rud et al,25 in Denmark, question the
utility of all 3 evaluated clinical decision rules (OST,
ORAI, and SCORE) to select healthy perimenopau-
sal and early postmenopausal women (mean age
of the cohort 50.5 years) for DEXA. 
Our results must be interpreted in the light of se-
veral limitations. 
First, we did not test all decision algorithms that
have been published, rather excluding more com-
plex formulas. The decision may be arguable but
the simplicity of the tool is decisive for its useful-
ness in clinical practice.
Second, our series is affected by historical chan-
ges; it is possible that the pattern of oestrogen use
in our area has changed, as a consequence of the
results of the Women’s Health Initiative trial.36, 37
This circumstance could slightly change the data
concerning the ORAI and the ABONE.
Self selection of volunteers may have biased our
population sample towards higher levels of educa-
tion and income. However, the impact of such de-
viations on the evaluation of the performance of
theses indices is probably minor, as they are desig-
ned for application in practice without considera-
tion of other factors. 
The practical application of these decision ru-
les and risk indices in facilitating clinical decisions
and promoting rational use of resources should be
explored further, including all potential benefits
as well as harms, such as those derived of labelling
women at high risk for osteoporosis.38 The use of
such algorithms should not preclude due conside-
ration of other less common but important risk
factors. Women with a prior fragility fracture are at
high risk for osteoporosis and recurrent fracture
and should be referred for BMD testing to facilita-
te treatment decisions, irrespective of other con-
sideration.23, 39 Similarly, women with major risk
factors for secondary osteoporosis should discuss
bone health and BMD testing independent of the-
se decision rules.
A larger population-based study would be va-
luable to assure the scientific reliability of our fin-
dings and a direct comparison with usual clinical
practice would also be valuable to determine if de-
cision rule approaches provide more optimal use
of BMD testing.40
The major issue with this study may reside in the
economical methodology employed. It certainly
represents a major simplification of reality. Nume-
rous factors, such as cost of time used for screening
and for testing, cost and effectiveness of medica-
tion and its follow-up, and indirect costs of fractu-
re have all been left out. However, the assumptions
were similar to all age groups and algorithms, al-
lowing a cross comparison under similar, although
not precise, conditions. Clearly the costs and sa-
vings presented here should not be taken as a ri-
gorous representation of reality but rather as an
index for cross-comparison. We believe that this is
compensated by simplicity allowing for the use of
descriptors and concepts that are inspired and ea-
sily understood by the practicing clinician. Ulti-
mately, he is the one responsible for adopting any
strategy and for taking science to the benefit of in-
dividual patients and society.
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